Skip to Main Content

KMAP BULLETIN: Pharmaceutical Prior Authorization Updates – June 2026

Date: 07/15/26

KMAP GENERAL BULLETIN 26126 (PDF)

Effective with dates of service on or after June 30, 2026, the following medications will no longer have a Preferred Drug List (PDL) Prior Authorization (PA):

  • Omalizumab (Xolair®)

Effective dates of service on or after July 1, 2026, the following medications require Clinical Prior Authorization (PA):

  • Bosutinib (Bosulif®)
  • Semaglutide (Ozempic®)


Effective with dates of service on or after July 1, 2026, the following medications require PDL PA:

  • Bimatoprost (Zolymbus™)
  • Clonidine 0.05mg tablet
  • Gabapentin (Relgaabi®) 200mg
  • Tolmetin sodium 200mg tablet


Note: The effective dates of the policy are June 30, 2026, and July 1, 2026.

The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.